LIPOPROTEIN(A) IN DIABETIC-PATIENTS WITH AND WITHOUT CHRONIC-RENAL-FAILURE

被引：55

作者：

GUILLAUSSEAU, PJ ^{[1
]}

PEYNET, J ^{[1
]}

CHANSON, P ^{[1
]}

LEGRAND, A ^{[1
]}

ALTMAN, JJ ^{[1
]}

POUPON, J ^{[1
]}

NGUYEN, M ^{[1
]}

ROUSSELET, F ^{[1
]}

LUBETZKI, J ^{[1
]}

机构：

[1] UNIV PARIS 07,HOP LARIBOISIERE,BIOCHEM LAB,F-75221 PARIS 05,FRANCE

来源：

DIABETES CARE | 1992年 / 15卷 / 08期

关键词：

D O I：

10.2337/diacare.15.8.976

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OBJECTIVE - To examine the distribution of Lp(a) plasma levels in patients with IDDM and NIDDM, and in nondiabetic and IDDM patients with chronic renal failure. RESEARCH DESIGN AND METHODS - Cross-sectional study of Lp(a) plasma levels in a population of diabetic patients with stable metabolic control, with simultaneous determination of plasma lipids, fasting plasma glucose, and HbA1. Thirty-six patients with IDDM, 90 with NIDDM, and 41 with chronic renal failure (20 IDDM, 21 nondiabetic) were compared with 78 control subjects. RESULTS - Lp(a) plasma levels were significantly higher in IDDM and NIDDM patients, as well as in nondiabetic and IDDM patients with chronic renal failure compared with control subjects. No correlation was observed between Lp(a) and lipid plasma levels, fasting plasma glucose, and HbA1. CONCLUSIONS - Lp(a) may contribute to the increased prevalence of atherosclerotic disease in diabetic patients and patients with chronic renal failure, especially in IDDM patients whose lipoprotein pattern was not different from that of the control group.

引用

页码：976 / 979

页数：4

共 19 条

[1] INCREASED SERUM LEVELS OF LIPOPROTEIN(A) IN DIABETES-MELLITUS AND THEIR REDUCTION WITH GLYCEMIC CONTROL [J].

BRUCKERT, E ;

DAVIDOFF, P ;

GRIMALDI, A ;

TRUFFERT, J ;

GIRAL, P ;

DOUMITH, R ;

THERVET, F ;

DEGENNES, JL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (01) :35-36

[2] THE DETERMINATION OF LIPOPROTEIN LP(A) BY RATE AND ENDPOINT NEPHELOMETRY [J].

CAZZOLATO, G ;

PRAKASCH, G ;

GREEN, S ;

KOSTNER, GM .

CLINICA CHIMICA ACTA, 1983, 135 (02) :203-208

[3]

DHALEN GH, 1986, CIRCULATION, V74, P758

[4]

DIEPLINGER H, 1990, ARTERIOSCLEROSIS, V10, P860

[5]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

[6] COMPARISON OF HBA1 AND FRUCTOSAMINE IN DIAGNOSIS OF GLUCOSE-TOLERANCE ABNORMALITIES [J].

GUILLAUSSEAU, PJ ;

CHARLES, MA ;

PAOLAGGI, F ;

TIMSIT, J ;

CHANSON, P ;

PEYNET, J ;

GODARD, V ;

ESCHWEGE, E ;

ROUSSELET, F ;

LUBETZKI, J .

DIABETES CARE, 1990, 13 (08) :898-900

[7] DECREASE OF LIPOPROTEIN(A) WITH IMPROVED GLYCEMIC CONTROL IN IDDM SUBJECTS [J].

HAFFNER, SM ;

TUTTLE, KR ;

RAINWATER, DL .

DIABETES CARE, 1991, 14 (04) :302-307

[8] MAGNITUDE AND DETERMINANTS OF CORONARY-ARTERY DISEASE IN JUVENILE-ONSET, INSULIN-DEPENDENT DIABETES-MELLITUS [J].

KROLEWSKI, AS ;

KOSINSKI, EJ ;

WARRAM, JH ;

LELAND, OS ;

BUSICK, EJ ;

ASMAL, AC ;

RAND, LI ;

CHRISTLIEB, AR ;

BRADLEY, RF ;

KAHN, CR .

AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (08) :750-755

[9] LIPOPROTEIN(A) LEVELS IN BLACK-AND-WHITE CHILDREN AND ADOLESCENTS WITH IDDM [J].

LEVITSKY, LL ;

SCANU, AM ;

GOULD, SH .

DIABETES CARE, 1991, 14 (04) :283-287

[10]

LOPESVIRELLA MF, 1981, DIABETOLOGIA, V21, P216, DOI 10.1007/BF00252657

← 1 2 →